- Home
- » Tags
- » Lexatumumab
Top View
- (INN) for Biological and Biotechnological Substances
- Strategies to Obtain Diverse and Specific Human Monoclonal
- Clinical Cancer Cancer Therapy: Clinical Research
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- A61K9/51 (2006.01) — with International Search Report (Art
- Role of Immunotherapy in Ewing Sarcoma
- N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity Against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
- Mapatumumab and Lexatumumab Induce Apoptosis in TRAIL-R1 and TRAIL-R2 Antibody-Resistant NSCLC Cell Lines When Treated in Combination with Bortezomib
- Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients With
- Activating Death Receptor DR5 As a Therapeutic
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- Assessment of the Evolution of Cancer Treatment Therapies
- Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
- Modeling Hepatocellular Toxicity of Enavatuzumab, a Humanized Anti-Tweakr Antibody
- Pharmaabkommen A1 E
- (12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
- Com(2010)0397
- University of Groningen Targeted Therapy, Molecular Imaging And
- Principles of Antibody-Mediated TNF Receptor Activation
- (12) United States Patent (10) Patent No.: US 9,345,770 B2 Storkus Et Al
- The Honorable Shara Aranoff Chairman United States International Trade Commission 500 E Street, S.W. Washington, DC 20436 Dear C
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Diapositiva 1
- Monoclonal Antibodies: an Emerging Class of Therapeutics in Non Small Cell Lung Cancer
- International Journal of Current Advanced Research
- Us 2019 / 0202839 A1
- Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- (INN) for Biological and Biotechnological Substances
- Ramesh Rengan, MD Ph.D. Radiation Therapy Contraindications And
- Medicines & Vaccines in Development for Cancer
- Ep 3088005 A1
- Assessment of the Evolution of Cancer Treatment Therapies
- Pre-Activation of the P53 Pathway Through Nutlin-3A Sensitises Sarcomas to Drozitumab Therapy
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- On the TRAIL to Successful Cancer Therapy? Predicting and Counteracting Resistance Against TRAIL-Based Therapeutics
- (12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al